+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: A retrospective observational study

Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: A retrospective observational study

Indian Journal of Cancer 53(4): 592-594

Colistin-based combination therapy (CCT) is extensively used to treat infections due to carbapenem-resistant Gram-negative bacteria (CRGNB). There are no data available from India on the usefulness of combination therapy, especially in the oncology setup. The aim of this study was to analyze the clinical effectiveness of CCT over monotherapy in patients with CRGNB. We conducted a retrospective, observational study of patients with CRGNB bloodstream infections in our oncology and bone marrow transplant center. Over a 3-year study period (2011-2014), we could identify 91 patients satisfying study criteria. There was no statistically significant difference in the 28-day mortality between monotherapy and combination therapy arms (mono n = 26, mortality 10 (38.5%); combination n = 65, mortality 28 (40%); P = 0.886). Neutropenic patients with Enterobacteriaceae bloodstream infections performed better with combination therapy (mono n = 7, mortality 6 (85.7%); combination therapy n = 22, mortality 8 (36.4%); P = 0.035). There was no significant difference in the 28-day mortality between the two treatment arms in other subgroups. Our study did not find CCT superior to colistin monotherapy in patients with CRGNB blood stream infections; except in the subgroup of neutropenic patients with Enterobacteriaceae bloodstream infections, where combination therapy performed better.

(PDF emailed within 0-6 h: $19.90)

Accession: 059987430

Download citation: RISBibTeXText

PMID: 28485360

DOI: 10.4103/0019-509X.204767

Related references

Monotherapy versus Combination Therapy against Nonbacteremic Carbapenem-resistant Gram-negative Infections: A Retrospective Observational Study. Indian Journal of Critical Care Medicine 21(12): 825-829, 2018

Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 7(8): -, 2018

Combination therapy for carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial ChemoTherapy 69(9): 2305-2309, 2015

Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Review of Anti-Infective Therapy 11(12): 1333-1353, 2014

Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study. Biomed Research International 2016: 8395268-8395268, 2017

Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scandinavian Journal of Infectious Diseases 46(1): 1-8, 2014

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrobial Agents and ChemoTherapy 41(5): 1127-1133, 1997

Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrobial Agents and ChemoTherapy 60(7): 4013-4022, 2017

Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study. Journal of Antimicrobial ChemoTherapy 70(11): 3146-3153, 2016

In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrobial Agents and ChemoTherapy 56(7): 3753-3757, 2012

Rapid antibiotic combination testing for carbapenem-resistant Gram negative bacteria within 6h using adenosine triphosphate bioluminescence. Antimicrobial Agents and ChemoTherapy: -, 2018

In Vitro Activity of MK-7655, a Novel beta-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria. 2012

Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: A commentary. International Journal of Antimicrobial Agents 11(1): 7-12, 1999

Monotherapy versus beta-lactam-aminoglycoside combination therapy for gram-negative bacteremia. Antimicrobial Agents and ChemoTherapy 41(11): 2593-2594, 1997

Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING). Bmj Open 6(7): E011500-E011500, 2016